Reported Earlier: Aptevo Therapeutics Announces A New Solid Strategy Designed To Fight Cancer On Multiple Fronts; Files A Patent Application Covering A Proprietary Nectin-4 X PD-L1 Dual-Targeting Backbone Designed To Strengthen Aptevo's Oncology Pipeline
Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced a new solid tumor strategy designed to fight cancer on multiple
Aptevo filed a patent for a new cancer-fighting tool that targets two things at once instead of one. When a company patents new ideas, it shows they're building stronger products—watch to see if their cancer treatments work better in testing.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.